Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 812-822

  Voelkl, Jakob ^a   Alesutan, Ioana ^a   Leibrock, Christina B ^a   Quintanilla Martinez, Leticia ^a   Kuhn, Volker ^b   Feger, Martina ^a   Mia, Sobuj ^a   Ahmed, Mohamed S E ^a   Rosenblatt, Kevin P ^c   Kuro O, Makoto ^d   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d University of Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CALCITRIOL; CALCIUM; CYSTATIN C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MESSENGER RNA; SPIRONOLACTONE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR RUNX2;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; BODY WEIGHT; BONE DEVELOPMENT; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CALCIFICATION; KIDNEY PARENCHYMA; LIFESPAN; LUNG CALCIFICATION; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SOFT TISSUE CALCIFICATION; UREA NITROGEN BLOOD LEVEL;

ALDOSTERONE; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MICE; MICE, KNOCKOUT; OSTEOBLASTS; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TRANSCRIPTION FACTOR PIT-1; VASCULAR CALCIFICATION;

EID: 84873371137     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64093     Document Type: Article

References (73)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 suppl):S16-S23.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938-942.
3. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-1740.
4. Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14(1):3-12.
5. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20(7):1453-1464.
6. Hu MC, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22(1):124-136.
7. Kuro O. Phosphate and Klotho. Kidney Int Suppl. 2011; (121): S20-S23.
8. Kuro-o M, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45-51.
9. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1, 25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology. 2002;143(2):683-689.
10. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003;14(9 suppl 4):S300-S304.
11. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627-2633.
12. Steitz SA, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147-1154.
13. Jono S, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10-E17.
14. Nowik M, et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch. 2008;457(2):539-549.
15. Son BK, et al. Adiponectin antagonizes stimulatory effect of tumor necrosis factor-alpha on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5'-monophosphate-activated protein kinase. Endocrinology. 2008;149(4):1646-1653.
16. Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun. 2010;391(1):1087-1092.
17. Sun Y, et al. Smooth muscle cell-specific runx2 deficiency inhibitsvascular calcification. Circ Res. 2012;111(5):543-552.
18. Al Aly Z, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol. 2007;27(12):2589-2596.
19. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115(5):1210-1220.
20. Liu H, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317(5839):803-806.
21. Caverzasio J, Manen D. Essential role of Wnt3amediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology. 2007;148(11):5323-5330.
22. Shroff RC, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118(17):1748-1757.
23. Maekawa Y, et al. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine. 2009;35(3):341-346.
24. Sanz-Rosa D, et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens. 2005;23(6):1167-1172.
25. Lim K, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012;125(18):2243-2255.
26. Takei Y, et al. Stanniocalcin 2 is associated with ectopic calcification in alpha-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smooth muscle cells. Bone. 2012;50(4):998-1005.
27. Fischer SS, et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol. 2010;299(5):F1171-F1177.
28. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21(1):98-101.
29. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107(19):2512-2518.
30. Quaschning T, Ruschitzka F, Shaw S, Luscher TF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension. 2001;37(2 part 2):801-805.
31. De Jager DJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782-1789.
32. Kuro-o M. Klotho and the aging process. Korean J Intern Med. 2011;26(2):113-122.
33. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643-650.
34. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007;27(4):799-805.
35. Wu SY, et al. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood). 2012;237(1):31-37.
36. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93(7):817-824.
37. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98(7):905-912.
38. Villa-Bellosta R, Bogaert YE, Levi M, Sorribas V. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol. 2007;27(5):1030-1036.
39. Villa-Bellosta R, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch. 2009;458(6):1151-1161.
40. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350(2):256-265.
41. Shin V, Zebboudj AF, Bostrom K. Endothelial cells modulate osteogenesis in calcifying vascular cells. J Vasc Res. 2004;41(2):193-201.
42. Kanno Y, Into T, Lowenstein CJ, Matsushita K. Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res. 2008;77(1):221-230.
43. Takeshita K, et al. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. Semin Thromb Hemost. 2002;28(6):545-554.
44. Stubbs JR, et al. Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18(7):2116-2124.
45. Morishita K, et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr. 2001;131(12):3182-3188.
46. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol. 2003;17(12):2393-2403.
47. Block GA, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407-1415.
48. Aoshima Y, et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-alpha. Nephrol Dial Transplant. 2012;27(5):1800-1806.
49. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant. 2006;21(4):889-897.
50. Al Aly Z. Vascular calcification in uremia: what is new and where are we going? Adv Chronic Kidney Dis. 2008;15(4):413-419.
51. Hamirani YS, et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis. 2008;201(1):1-7.
52. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev. 2010;3(2):109-121.
53. De Borst MH, Vervloet MG, Ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22(9):1603-1609.
54. Narumiya H, et al. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells. Cardiovasc Res. 2004;64(2):331-336.
55. Rakugi H, et al. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine. 2007;31(1):82-87.
56. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol. 1999;31(6):1175-1184.
57. Tang C, Pathare G, Michael D, Fajol A, Eichenmuller M, Lang F. Downregulation of Klotho expression by dehydration. Am J Physiol Renal Physiol. 2011;301(4):F745-F750.
58. Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatol Int. 2011;5(2):738-739.
59. Moghetti P, et al. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1999;84(4):1250-1254.
60. McRobb L, Handelsman DJ, Heather AK. Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology. 2009;150(2):841-848.
61. Son BK, et al. Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification. J Biol Chem. 2010;285(10):7537-7544.
62. Haruna Y, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A. 2007;104(7):2331-2336.
63. Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis. 2011;58(5):826-834.
64. Koleganova N, et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant. 2009;24(8):2488-2496.
65. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012;73(3):447-454.
66. Nakano-Kurimoto R, et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol. 2009;297(5):H1673-H1684.
67. Gui T, et al. MicroRNAs that target Ca (2+) transporters are involved in vascular smooth muscle cell calcification. Lab Invest. 2012;92(9):1250-1259.
68. Chiga M, et al. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. Kidney Int. 2008;74(11):1403-1409.
69. Lippoldt A, Gross V, Bohlender J, Ganten U, Luft FC. Lifelong angiotensin-converting enzyme inhibition, pressure natriuresis, and renin-angiotensin system gene expression in transgenic (mRen-2) 27 rats. J Am Soc Nephrol. 1996;7(10):2119-2129.
70. Axel DI, Brehm BR, Wolburg-Buchholz K, Betz EL, Koveker G, Karsch KR. Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells. J Vasc Res. 1996;33(4):327-339.
71. Riessen R, Axel DI, Fenchel M, Herzog UU, Rossmann H, Karsch KR. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol. 1999;94(5):322-332.
72. Voelkl J, et al. Sgk1 sensitivity of Na (+)/H (+) exchanger activity and cardiac remodeling following pressure overload. Basic Res Cardiol. 2012;107(2):1-15.
73. Mossbrugger I, Hoelzlwimmer G, Calzada-Wack J, Quintanilla-Martinez L. Standardized morphological phenotyping of mouse models of human diseases within the German Mouse Clinic. Verh Dtsch Ges Pathol. 2007;91:98-103.